CAPR - Capricor Therapeutics GAAP EPS of -$0.31 beats by $0.03 revenue of $0.96M beats by $0.96M
2023-03-15 16:03:53 ET
- Capricor Therapeutics press release ( NASDAQ: CAPR ): Q4 GAAP EPS of -$0.31 beats by $0.03 .
- Revenue of $0.96M beats by $0.96M .
- The Company’s cash, cash equivalents and marketable securities totaled approximately $41.4 million as of December 31, 2022 compared to approximately $34.9 million on December 31, 2021.
- Outlook: Capricor believes that based on the current operating plan and financial resources, its available cash, cash equivalents and marketable securities will be sufficient to cover anticipated expenses and capital requirements into the fourth quarter of 2024. This expectation includes the upfront payment of $12 million pursuant to our Japan distribution agreement which we expect to receive in the first quarter of 2023 and excludes any additional potential milestone payments under its exclusive commercialization and distribution agreements with Nippon Shinyaku as well as any strategic use of capital not currently in the Company’s base-case planning assumptions.
For further details see:
Capricor Therapeutics GAAP EPS of -$0.31 beats by $0.03, revenue of $0.96M beats by $0.96M